drugset / Trial / NCT06254599
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase 3 study to evaluate the efficacy and safety of SY-3505 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic therapy.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Crizotinib | Small molecule | 250 mg | Oral |
| Subject | Ficonalkib | Small molecule | 600 mg | Oral |